Post-Traumatic Headache | Galantamine in the Treatment of Post-Traumatic Headache
Post-Traumatic Headache research study
What is the primary objective of this study?
Most patients with CPTH present with additional major cognitive, behavioral and somatic problems. Most drugs used currently have a negative influence on cognition. Therefore, treatment strategies addressing both the headache and cognitive disturbances in patients with CPTH are necessary. (CPTH; Chronic Post Traumatic Headache).
Who is eligible to participate?
Inclusion Criteria: Age range 18-75 CPTH according to ICHD-2 Fertile woman using adequate birth control Willing and able to give informed consent Willing and able to complete the entire course of the study to comply with study instructions Stable does of preventive medication - Exclusion Criteria: Subject is pregnant or lactating Significant medical or psychiatric disease Previous failure to 4 or more adequate trials of preventive medication Patient on non-stable dose of medication used to prevent CPTH -
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: July 2005
Completed Date: August 2005
Phase: Phase 4
Primary Outcome: Primary Headache Efficacy Measure; number of pain free days after 3 months
Secondary Outcome: Consumption of rescue medication
Study sponsors, principal investigator, and references
Principal Investigator: Alan Rapoport, MD
Lead Sponsor: Rapoport, Alan, M.D.
Collaborator: Ortho-McNeil Neurologics, Inc.